Evidence map›Paper›PMID 42402813›Full record

ArticleOncoimmunology2026

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Tithi Ghosh Halder, Erin Kelley, Jorge Soria-Bustos, Trason Thode, Serina Ng, Taylor Bargenquast, Alexis Weston, Ryan Rodriguez Del Villar, Mohan Kaadige, Erkut Borazanci and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Tithi Ghosh HalderCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.ORCID 0000-0002-4292-1153
Erin KelleyTranslational Genomics Research Institute (TGen), Phoenix, AZ, USA.
Jorge Soria-BustosTranslational Genomics Research Institute (TGen), Phoenix, AZ, USA.
Trason ThodeCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Serina NgCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Taylor BargenquastCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Alexis WestonCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Ryan Rodriguez Del VillarTranslational Genomics Research Institute (TGen), Phoenix, AZ, USA.
Mohan KaadigeCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Erkut BorazanciCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Michael GordonCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Justin MoserCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Frank TsaiCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Saul J PricemanDepartment of Hematology and Hematopoietic Cell Transplantation and T Cell Therapeutics Research Laboratories, City of Hope, Duarte, CA, USA.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation and T Cell Therapeutics Research Laboratories, City of Hope, Duarte, CA, USA.
Yan XingDepartment of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
John A AltinTranslational Genomics Research Institute (TGen), Phoenix, AZ, USA.
Raffaella SoldiCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.
Sunil SharmaCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-infiltrating lymphocyte (TIL) therapy, which involves extracting, expanding, and reinfusing immune cells to target cancer cells, has shown promise in melanoma treatment, but requires optimization for broader efficacy. The success of TIL therapy depends on the recognition of tumor-associated antigens, but neoantigen-reactive T-cells are often rare and exhausted in less immunogenic malignancies. Isolating T cells enriched in neoantigen reactivity prior to

Indexed as

Antigens, NeoplasmImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingMelanomaPeptidesAnimalsCell Line, TumorFemaleHumansMicePrecision MedicineProof of Concept StudyXenograft Model Antitumor AssaysAntigens, NeoplasmPeptidesAdoptive cell therapyimmunotherapyneoantigensPepSeqSNAP-TILtumor-infiltrating lymphocytes

Identifiers

PMID42402813
PMCPMC13348959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.